勃起功能障碍患者的治疗偏好:随机对照试验的系统审查
Celeste Manfredi1,2, Antonio Franco3,4, Francesco Ditonno2,5
1Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
Minerva urology and nephrology
|March 1, 2024
概括
患有勃起功能障碍 (ED) 的患者往往更喜欢tadalafil而不是sildenafil,并且根据需要使用tadalafil而不是每日剂量. 然而,这些偏好是基于具有偏差高风险的研究.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
- 患者报告的结果
背景情况:
- 了解患者的治疗偏好 (PTP) 是指导勃起功能障碍 (ED) 治疗和改善患者遵守的关键.
- 这一系统性审查评估了过去25年在ED患者中PTP的文献.
研究的目的:
- 系统地审查和描述文献,评估ED患者的治疗偏好.
- 综合有关患者在不同ED治疗选择中的选择的证据.
主要方法:
- 在多个数据库中进行全面的文献搜索 (截至2023年6月),搜索1998年以来发表的文章.
- 包括随机对照试验 (RCT) 和随机对照试验的后期分析,比较ED治疗方法.
- 使用RoB 2工具和Mulhall-Montorsi模型进行叙述数据合成和偏差风险 (RoB) 评估.
主要成果:
- 包括14个RCT和4个后期分析,涉及6,841名患者.
- 所有RCT都被评估为具有高偏差风险;没有用于PTP的验证工具.
- 西尔德纳菲尔比安慰剂 (78-100%) 和ICI (70%) 更受欢迎. 塔达拉菲尔比锡尔德纳菲尔 (66-73%) 更受青,塔达拉菲尔在需要时超过每周3次 (57-59%).
结论:
- 现有的RCT表明ED患者更喜欢西尔德纳菲尔而不是ICI,塔达拉菲尔而不是西尔德纳菲尔,以及根据需要的塔达拉菲尔而不是塔达拉菲尔每周3次.
- 这些发现表明患者更喜欢特定的ED治疗方式.
- 所有结论都受到包括在内的研究中发现的偏差高风险的限制.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
157
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
157
Disorders of the Male Reproductive System
414
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
414
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K


